Hepion Pharmaceuticals Inc Stock Price, News & Analysis

Hepion Pharmaceuticals (NASDAQ:HEPA) will join the Russell Microcap® Index on June 28, enhancing its visibility to institutional investors. This membership is seen as a milestone in Hepion's efforts to increase shareholder value through the clinical development of its lead candidate, CRV431, aimed at treating NASH and liver diseases. The Russell indexes are widely regarded benchmarks for $10.6 trillion in assets. Inclusion in these indexes could attract new investors and facilitate growth opportunities for the company.

Hepion Pharmaceuticals (NASDAQ:HEPA) announced the completion of patient recruitment for its Phase 2a 'AMBITION' clinical trial focused on treating NASH. The trial enrolled patients in the 225 mg CRV431 cohort, overcoming delays due to COVID-19 and adverse weather conditions. Following 28 days of dosing, subjects will be monitored for an additional 14 days to assess safety, tolerability, pharmacokinetics, and early efficacy biomarker analyses of CRV431. The study aims to gather critical data using Hepion's AI-POWR™ platform to enhance precision medicine approaches for NASH treatment.

Hepion Pharmaceuticals (NASDAQ:HEPA) has announced a virtual presentation by Dr. Patrick Mayo, Senior VP of Clinical Pharmacology, at the 4th Global NASH Congress, focusing on the development of CRV431, its lead candidate for treating non-alcoholic steatohepatitis (NASH). Dr. Mayo discussed the impact of cyclophilins on disease processes and the application of AI-POWR™, Hepion's AI platform, in optimizing clinical trials. The company aims to streamline trial processes and enhance efficacy through predictive modeling and bioinformatics.

Hepion Pharmaceuticals (NASDAQ:HEPA) announced positive results from an in vivo study of CRV431 targeting non-alcoholic steatohepatitis (NASH). The study showed a 47% reduction in fibrosis in a Diet-Induced Animal Model Of Non-alcoholic fatty liver Disease (DIAMOND). CRV431 demonstrated consistent antifibrotic effects across multiple studies, with ongoing Phase 2a clinical trials evaluating safety and pharmacokinetics in NASH patients. Hepion aims to leverage its AI-POWR™ platform for further biomarker identification and clinical efficacy evaluation.

Hepion Pharmaceuticals (NASDAQ:HEPA) announced its participation in the Benzinga Biotech Small Cap Conference on March 25, 2021. CEO Dr. Robert Foster will provide a corporate overview at 9:45 a.m. Eastern Time, while Dr. Patrick Mayo will join a panel discussion on NASH treatments at 1:00 p.m. Eastern Time. The company's lead drug candidate, CRV431, targets non-alcoholic steatohepatitis (NASH) and demonstrates potential in reducing liver fibrosis and tumor burden in experimental models. Hepion also leverages its AI-POWR™ platform to optimize patient treatment outcomes.

Hepion Pharmaceuticals (NASDAQ:HEPA) announced its participation in the NASH-TAG 2021 Conference, taking place virtually from March 11-13, 2021. CEO Dr. Robert Foster will deliver an oral presentation on the positive top-line data from the Phase 2a ‘AMBITION’ clinical trial of CRV431, an innovative cyclophilin inhibitor. The presentation will highlight how the AI-POWR™ platform is utilized in optimizing study design for the upcoming Phase 2b trial. The presentation is scheduled for March 13, 2021, from 7:15 to 7:30 p.m. MT. More details can be found on the company's website.

Hepion Pharmaceuticals (NASDAQ:HEPA) announced the closing of a public offering of 44,200,000 shares at $2.00 each, raising $88.4 million in gross proceeds. After expenses, the net proceeds amount to approximately $82.1 million. The funds will primarily support research and development activities along with general corporate needs. The offering was managed by ThinkEquity. Hepion's lead drug candidate, CRV431, targets liver diseases, particularly NASH, and shows promise for broader therapeutic applications.

Hepion Pharmaceuticals announced a public offering of 44,200,000 shares of common stock at $2.00 per share, raising gross proceeds of $88.4 million. The offering, managed by ThinkEquity, is set to close on February 18, 2021. The funds will support research and development activities, along with working capital. Hepion's lead drug candidate, CRV431, targets liver diseases, particularly non-alcoholic steatohepatitis (NASH). The company utilizes its AI platform, AI-POWR™, to enhance drug development and patient response identification.

Hepion Pharmaceuticals (NASDAQ:HEPA) announced a proposed public offering of common stock, with all shares being sold by the Company. The offering is managed by ThinkEquity and is subject to market conditions. Proceeds will primarily be directed towards research and development, product development, and general corporate purposes. The securities are offered under a shelf registration statement previously filed with the SEC. The Company’s lead drug candidate, CRV431, targets liver disease.